But ahead of Swiss President Guy Parmelin's meeting with European Commission president Ursula von der Leyen, Bern has kept its cards close to its chest on what approach it plans to take.
The bloc is trying to learn the lessons after largely missing out on the internet revolution and failing to produce any major competitors to match the giants of Silicon Valley or their Chinese counterparts.
Ursula von der Leyen said the earlier deliveries, which will start this month, will take total supplies to the EU from Pfizer to 250 million doses in the second quarter of this year.
She also confirmed the Commission was in talks with the two companies for a new contract for 1.8 billion doses to be delivered in 2022 and 2023, confirming a Reuters report last week.
It all centred on an awkward moment at the start of talks between von der Leyen, European Council President Charles Michel and Turkish leader Recep Tayyip Erdogan in Ankara on Tuesday.
Mamer said von der Leyen decided not to make "an issue out of it" and in the conversation brought up women's rights and the Istanbul Convention on violence against women, from which Turkey withdrew last month.
The EU threatened Ankara with sanctions last year after a flare-up in a decades-old dispute between Turkey and Greece over maritime jurisdiction and energy resources in the Mediterranean.
We underlined the importance of sustained de-escalation and of further strengthening confidence building to allow for a more positive EU-Turkey agenda.
The EU has already set up special oversight of vaccine exports in which manufacturers contracted to supply Europe must declare if they intend to export doses outside the bloc.
"If this situation does not change, we will have to reflect on how to make exports to vaccine-producing countries dependent on their level of openness," EU Commission President Ursula von der Leyen told a news conference.
"We are ready to use whatever tools we need to deliver on that," von der Leyen said.
The EU has so far approved three vaccines -- Pfizer-BioNTech, Moderna and AstraZeneca-Oxford. Three other vaccines are under "rolling review" by the Amsterdam-based EMA -- Novavax, CureVac and Russia's Sputnik.